Immunotherapy for gastric cancer: dilemmas and prospect

• Published in: Briefings in functional genomics Vol. 18; no. 2; pp. 107 - 112
• Main Authors: Zhao, Qingfang, Cao, Liang, Guan, Lulu, Bie, Liangyu, Wang, Saiqi, Xie, Bojian, Chen, Xiaobing, Shen, Xiaokun, Cao, Feiling
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 22.03.2019
• Subjects: biomarkers; breast neoplasms; death; genome; genomics; immune system; immunotherapy; lung neoplasms; prognosis; stomach neoplasms; survival rate; immunogenomics; immune checkpoint inhibitor; gastric cancer; biomarkers
• ISSN: 2041-2657; 2041-2657
• DOI: 10.1093/bfgp/ely019

Abstract Gastric cancer remains the second most common cause of cancer-related death worldwide. Because of the poor prognosis of late-stage gastric cancer patients, it is imperative to develop new strategies to improve the survival rate of this disease. Currently, immunotherapy is considered as an innovative approach for cancers such as lung cancer, gastric cancer and breast cancer. In fact, previous works have revealed promising results in this field. With further understanding of immunogenomics of gastric cancer, new immune checkpoint regulators could become more important. In addition, whole-genome sequencing and genome editing provide us with more information on the heterogeneity of gastric cancer, showing helpful tools to identify new predictive biomarkers and to achieve personalized treatment. Further research and better understanding of the functions of immune system will enhance immunotherapy treatment in the future.